Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity

Figure 16 Adverse drug reactions reported in ≥ 10% of liraglutide 3 mg recipients with a higher incidence than placebo stratified by system. GI: Dyspepsia, abdominal pain, dry mouth, gastritis, gastroesophageal reflux disease, flatulence, eructation and abdominal distension were also more prevalent in liraglutide treated participants but occurred with incidence ≤ 10%, not shown; 6.2% with Saxenda vs 0.8% with placebo discontinued treatment as a result of gastrointestinal adverse reactions; CNS: Dizziness, malaise and fatigue occurred were more also prevalent in liraglutide treated participants but occurred with incidence ≤ 10%, not shown; Metabolic: Liraglutide reduces blood glucose and thus, there is a potential for hypoglycaemia to occur. In the SCALE diabetes trial severe hypoglycemia occurred in 3 (0.7%) of 422 Saxenda-treated patients and in none of the 212 placebo-treated patients. In clinical trials involving patients without T2DM[42,43,205,206] no systematic reporting of hypoglycemia occurred but spontaneously reported symptomatic episodes potentially hypoglycemic in cause were reported by 1.6% (46/2962) of liraglutide 3 mg and 1.1% of (19/1729) placebo treated non diabetic patients. T2DM: Type 2 diabetes mellitus; GI: Gastrointestinal; CNS: Central nervous system.